tiprankstipranks
DaVita Inc. (DVA)
NYSE:DVA
US Market
Want to see DVA full AI Analyst Report?

DaVita (DVA) Earnings Dates, Call Summary & Reports

1,077 Followers

Earnings Data

Report Date
Aug 05, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
3.81
Last Year’s EPS
2.95
Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call reflected a generally positive tone: the company beat Q1 expectations, raised and narrowed full-year adjusted operating income and EPS guidance, demonstrated productivity-led cost improvements, and highlighted strong IKC clinical and savings performance. Material investments in technology and AI were emphasized as strategic drivers of future clinical and operational outperformance. Offsetting items included near-term pressure from higher G&A (driven by technology spend), an IKC operating loss, modest treatment declines versus prior year, ACA enrollment/mix uncertainty that could pressure revenue per treatment later in the year, and unchanged free cash flow guidance. On balance, the positive beats, guidance raise, and structural investments outweighed the near-term headwinds.
Company Guidance
Management raised and narrowed 2026 financial guidance after a strong Q1: adjusted operating income guidance is now $2.15–$2.25 billion (roughly $40M higher at the midpoint) and adjusted EPS guidance is $14.10–$15.20 per share; Q1 results included $482M of adjusted operating income (about $50M ahead of forecast), $2.87 adjusted EPS and $140M of free cash flow. They raised full‑year treatment volume growth to +25–50 bps (implying +50–75 bps in treatments per normalized day), after Q1 treatments were down ~20 bps YoY while treatments per normalized day rose ~40 bps; revenue per treatment grew ~4% YoY in Q1 (company expects 1–2% for the year), patient care cost per treatment was roughly flat to Q4, IKC posted a $19M operating loss and international OI was $30M, leverage was 3.34x EBITDA, Q1 debt expense was $145M (expected to run similar quarterly), and the prior ~$40M ACA headwind remains under review as enrollment trends look slightly favorable.
Beat on Adjusted Operating Income and EPS
Q1 adjusted operating income of $482 million and adjusted EPS of $2.87, with adjusted OI about $50 million ahead of forecast (roughly half from operational outperformance and half timing).
Raised Full-Year Financial Guidance
Company raised and narrowed 2026 guidance: adjusted operating income to $2.15B–$2.25B and adjusted EPS to $14.10–$15.20, driven primarily by higher volume forecast and lower patient care costs.
Volume and Utilization Improvement
Treatment volume slightly ahead of forecast; treatments per normalized day up ~40 basis points year-over-year in Q1. Full-year treatment volume guidance raised from flat to +25–50 bps (implying +50–75 bps in treatments per normalized day).
Revenue per Treatment Momentum (Q1)
Revenue per treatment increased approximately 4% year-over-year in Q1 (Joel cited ~+$17.50), with management attributing ~2/3 to normal rate/mix and ~1/3 to timing.
Cost Productivity and Patient Care Costs
Patient care cost per treatment was roughly flat to Q4, and lower-than-expected overall due to better-than-expected productivity improvements, supporting margin expansion.
IKC Clinical & Economic Performance
Integrated Kidney Care (IKC) delivered YoY improvements across 3 key CKCC measurements; company generated the highest total aggregate savings of any participant, driven by a 4.5% improvement in gross savings rate since program start.
Capital Allocation & Balance Sheet Discipline
Repurchased ~5 million shares (3M in Q1 and 2M post-quarter including Berkshire Hathaway transaction). Leverage at 3.34x consolidated EBITDA, within target range of 3.0–3.5x.
Strategic Technology Investments and AI Deployment
Investments in modernized data infrastructure and AI use cases (e.g., ScheduleHub scheduling tool and proprietary EMR) intended to improve caregiver productivity, operations and scale benefits over time.

DaVita (DVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DVA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2026
2026 (Q2)
3.81 / -
2.95
May 05, 2026
2026 (Q1)
2.33 / 2.87
243.50% (+0.87)
Feb 02, 2026
2025 (Q4)
3.24 / 3.40
2.2451.79% (+1.16)
Oct 29, 2025
2025 (Q3)
3.22 / 2.51
2.59-3.09% (-0.08)
Aug 05, 2025
2025 (Q2)
2.77 / 2.95
2.5913.90% (+0.36)
May 12, 2025
2025 (Q1)
1.95 / 2.00
2.38-15.97% (-0.38)
Feb 13, 2025
2024 (Q4)
2.13 / 2.24
1.8719.79% (+0.37)
Oct 29, 2024
2024 (Q3)
2.72 / 2.59
2.85-9.12% (-0.26)
Aug 06, 2024
2024 (Q2)
2.59 / 2.59
2.0824.52% (+0.51)
May 02, 2024
2024 (Q1)
1.95 / 2.38
1.5850.63% (+0.80)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DVA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 05, 2026
$157.04$193.88+23.46%
Feb 02, 2026
$111.19$134.73+21.17%
Oct 29, 2025
$126.56$118.75-6.17%
Aug 05, 2025
$140.52$127.81-9.04%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does DaVita Inc. (DVA) report earnings?
DaVita Inc. (DVA) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
    What is DaVita Inc. (DVA) earnings time?
    DaVita Inc. (DVA) earnings time is at Aug 05, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is DVA EPS forecast?
          DVA EPS forecast for the fiscal quarter 2026 (Q2) is 3.81.

            DaVita (DVA) Earnings News

            DaVita Tanks After Bleak Outlook and Q3 Earnings Disappoint
            Premium
            Market News
            DaVita Tanks After Bleak Outlook and Q3 Earnings Disappoint
            4y ago